Precigen, Inc. (PGEN) Stock Price & How to Invest
Last updated November 2026
Short answer
Precigen (PGEN) is a small-cap biopharmaceutical company that turned into a commercial-stage story in 2025 when the FDA approved Papzimeos, its gene-therapy immunotherapy for recurrent respiratory papillomatosis (RRP). You are buying a single-product launch ramp with a large addressable rare-disease niche, priced by the market well ahead of trailing revenue. The launch has moved faster than many expected: Precigen turned a quarterly profit in Q2 2026 and reached positive operating cash flow in Q3, yet the stock closed at $4.22 on November 20, 2026, down about 32% over the past month and roughly flat (about -1%) for the year.
PGEN stock price
As of 2026-11-20, Precigen, Inc. (PGEN) last closed at $4.21, up 8.5% over the past year. Over the past 52 weeks it has traded between $3.10 and $8.56.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Precigen, Inc.'s investor relations page. Walnut is informational, not investment advice.
PGEN key stats
At $4.21 on November 20, 2026, Precigen, Inc. (PGEN) has a market cap of $1.5B and a P/E of 38.3 on trailing earnings.
- Market cap
- $1.5B
- P/E (trailing)
- 38.3
- EPS (trailing 12 months)
- $0.11
- Price to book
- 18.0
- Beta
- 0.98
Market cap, P/E and yield are measured at the $4.21 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Precigen, Inc. (PGEN)?
The last two weeks for Precigen, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- PGEN closed at $4.21 on November 20, 2026, down 7.3% over the past five trading days (from $4.54).
- On November 16, 2026, B. Riley Securities lowered its target to $11.00 from $12.00 (Buy).
Precigen, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Precigen, Inc. (PGEN) do?
Precigen, Inc. is a Maryland-based biopharmaceutical company that develops precision medicines using its proprietary gene- and cell-therapy platforms, most notably the AdenoVerse gorilla-adenovector system, which the FDA has granted platform technology designation. For years it was a clinical-stage, cash-burning research company (formerly Intrexon), but in August 2025 it earned full FDA approval for Papzimeos (zopapogene imadenovec, formerly PRGN-2012), the first approved immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV 6 and 11 in which benign tumors recur in the airway and typically require repeated surgeries. Papzimeos is given as four subcutaneous injections over roughly 12 weeks and is designed to trigger an immune response against HPV-infected cells, and it carries FDA market exclusivity through August 14, 2032. Precigen also runs Exemplar, a small research-models and services business.
The investment picture is a classic single-product launch that is now showing in the income statement. Papzimeos net product sales were about $21.6 million in the first quarter of 2026, more than doubled in the second, and reached about $72.9 million in the third quarter, up 37% sequentially, for about $151 million launch to date. Q3 2026 total revenue, reported November 4, was about $74.1 million, roughly in line with expectations (EPS of $0.08 matched the Yahoo Finance consensus, while Zacks had looked for slightly more revenue), and net income was about $35.8 million. Operating cash flow turned positive at about $11.9 million, a quarter ahead of management's year-end target, and well over 500 patients have started treatment. Analysts expect about $240 million of revenue for 2026 and about $442 million in 2027, and Citizens raised its Papzimeos sales forecast after the quarter. The share price has gone the other way: at $4.22 on November 20, 2026 the stock is down about 32% in a month and 42% over three months, for a market capitalization near $1.5 billion, about 10 times trailing revenue of roughly $157 million. Bulls point to the unmet need, orphan pricing, broad payer coverage, a permanent J-code, and a European filing under EMA review. The counterweight is heavy single-asset concentration, a thin cash balance, the prospective launch of Inovio's competing therapy, and the ordinary risk that a rare-disease launch plateaus. Walnut is not an investment adviser and this is descriptive context, not a recommendation.
What's driving Precigen, Inc. (PGEN)?
1. Papzimeos launch ramp
Papzimeos is the entire near-term thesis, and launch metrics have been constructive: payer coverage for about 297 million US lives, a permanent J-code effective April 2026 that eases reimbursement, and well over 500 patients started on treatment (well over 300 completed) by the Q3 2026 report. Net product revenue went from about $21.6 million in Q1 2026 to more than double that in Q2 and about $72.9 million in Q3, up 37% sequentially, for about $151 million launch to date. Consensus calls for about $88 million of total revenue in Q4, so the pace of new-patient starts remains the metric that matters most.
2. From break-even target to profit
Management framed 2026 around reaching cash-flow break-even by year-end, funded by existing resources plus expected Papzimeos revenue. It got there early: Q2 2026 net income was about $20 million, Q3 net income about $35.8 million ($0.08 per diluted share), and Q3 operating cash flow was positive at about $11.9 million, a quarter ahead of guidance. Analysts model EPS of about $0.24 for 2026 and $0.62 for 2027. Sustained profitability would materially reduce the dilution risk that has long shadowed the stock, though trailing operating cash flow was still about -$73 million.
3. Geographic and pipeline expansion
A marketing application for Papzimeos, submitted in November 2025, has been validated and is under review with the EMA, and the product holds EU orphan drug designation, which could open a European revenue stream. Precigen also retains earlier-stage AdenoVerse and cell-therapy programs in oncology and infectious disease, though these are years from commercialization and carry the usual clinical-trial risk. Any pipeline read-outs are optional upside, not the base case.
What are the risks to Precigen, Inc. (PGEN)?
PGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once. The roughly $1.5 billion market cap still sits well ahead of trailing revenue of about $157 million, so the valuation embeds launch assumptions that leave little margin for disappointment; the shares fell about 32% in the month to November 20, 2026 and about 42% over three months despite a quarter of 37% sequential product growth, which shows how quickly sentiment can swing. Competition is moving closer: on the Q3 call management addressed the prospective launch of Inovio's INO-3107 and said it had planned for competition from the outset, citing payer policies, physician experience and treatment-site capabilities. Cash and investments were about $51 million at September 30, 2026 against about $98.6 million of debt, so a stall in the ramp could still require dilutive financing. The RRP niche, while high-need, is small, and the stock has historically been volatile and heavily shorted.
What is the Precigen, Inc. (PGEN) forecast?
3 analysts publish price targets on PGEN, averaging $13.67 as of November 2026, or +224.7% against the $4.21 share price on November 20, 2026. The published targets run from $11.00 to $18.00, a moderate spread, and the ratings split 3 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full PGEN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is PGEN a buy or a sell?
We give no verdict on Precigen, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Papzimeos launch ramp. Papzimeos is the entire near-term thesis, and launch metrics have been constructive: payer coverage for about 297 million US lives, a permanent J-code effective April 2026 that eases reimbursement, and well over 500 patients started on treatment (well over 300 completed) by the Q3 2026 report. The most optimistic published target, $18.00, assumes this works close to its best case.
The case against. PGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once. The most pessimistic target, $11.00, is roughly what PGEN is worth if this bites instead.
Read the full bull and bear case on PGEN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Precigen, Inc. (PGEN) split its stock?
No. Precigen, Inc. (PGEN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Precigen, Inc. (PGEN) valued?
Market cap, P/E and dividend yield at today's price are in the PGEN key stats above. The business figures below come from Precigen, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (Q3 2026 / TTM): ~$74.1M / ~$157M
- Papzimeos revenue (Q3 2026): ~$72.9M, +37% QoQ (~$151M launch to date)
- Net income (Q3 2026): ~$35.8M (diluted EPS $0.08 vs $0.08 est.)
- Cash / debt: ~$51M / ~$98.6M (Sep 30, 2026)
As of November 2026: Precigen moved from commercial launch to two profitable quarters and positive operating cash flow in just over a year, with Q3 2026 revenue of about $74.1 million and net income of about $35.8 million. After a 42% three-month drop the stock trades near 10 times trailing sales and about 38 times trailing earnings, far less stretched than in October, and it still trades on forward launch expectations: consensus revenue of about $240 million in 2026 and $442 million in 2027. The three analysts tracked by Yahoo Finance hold a mean target near $13.67, well above the $4.22 price.
Who competes with Precigen, Inc. (PGEN)?
RRP-focused therapy developers
The most direct comparison is Inovio Pharmaceuticals, whose INO-3107 is an HPV-targeted DNA immunotherapy in development for the same recurrent respiratory papillomatosis indication. Precigen's Papzimeos is first to market with full FDA approval, but Inovio is the clearest pipeline rival in this specific niche.
Gene- and cell-therapy biotechs
PGEN sits among small- and mid-cap gene- and cell-therapy companies pursuing rare and hard-to-treat diseases, a group that includes names like Krystal Biotech, uniQure, and other single-asset or platform biotechs. These peers share the same launch-execution and financing dynamics rather than competing for the same patients.
Broad immuno-oncology and HPV players
Precigen's earlier pipeline overlaps conceptually with large immuno-oncology and HPV-disease efforts from companies such as Merck (pembrolizumab and combinations). These are far larger and diversified, and are relevant mainly as a reminder that well-capitalized incumbents operate in adjacent HPV-driven disease areas.
What stocks are similar to Precigen, Inc. (PGEN)?
Other names that sit close to PGEN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Precigen, Inc. (PGEN)
There are three common ways to get PGEN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PGEN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where PGEN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Precigen, Inc. (PGEN)
PGEN is a launch-stage rare-disease biotech whose value now hinges almost entirely on how fast Papzimeos keeps scaling. With two profitable quarters and positive operating cash flow already reported, the question has shifted from whether the launch works to how large it gets, whether Europe follows, and how it holds up once Inovio's rival therapy reaches the market; the share price fell about 42% over three months even as revenue grew.
More on Precigen, Inc. (PGEN)
Whether PGEN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PGEN a buy or a sell?, and where the stock could go from here in the PGEN stock forecast.
For income investors, whether PGEN pays a dividend and how the payout looks is covered in does PGEN pay a dividend? And to weigh PGEN against a peer, read the full side-by-side comparisons: PGEN vs INO and PGEN vs DNA.
Wondering how PGEN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Precigen, Inc.
Ask Walnut's AI anything about PGEN and see how it fits what you own.
FAQ
What does Precigen do?
+
Precigen is a biopharmaceutical company that develops precision gene and cell therapies using platforms like its AdenoVerse gorilla-adenovector system. Its first and only commercial product is Papzimeos, an FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP).
What is Papzimeos?
+
Papzimeos (zopapogene imadenovec, formerly PRGN-2012) is Precigen's gene-therapy immunotherapy that received full FDA approval in August 2025 for adults with RRP. It is delivered as four subcutaneous injections over about 12 weeks and aims to trigger an immune response against cells infected by HPV 6 and 11. It has FDA market exclusivity through August 2032, and a European application is under EMA review.
Is Precigen profitable?
+
Yes, on a quarterly basis. Precigen reported net income of about $20 million in the second quarter of 2026 and about $35.8 million, or $0.08 per diluted share, in the third, after a net loss of about $7.9 million in the first quarter. Nine-month 2026 net income was about $47.9 million, and trailing twelve-month net income turned positive at about $24 million. Q3 operating cash flow was also positive, at about $11.9 million. Analysts expect full-year 2026 EPS of about $0.24.
How much revenue does Precigen generate?
+
Total revenue was about $23.3 million in Q1 2026, about $55 million in Q2 and about $74.1 million in Q3, almost all from Papzimeos, which has brought in about $151 million since launch. Trailing twelve-month revenue was about $157 million, up from about $9.7 million for all of 2025. Consensus calls for about $240 million in 2026 and about $88 million in Q4 alone.
What is Precigen's market cap?
+
Precigen's market capitalization was about $1.5 billion as of November 20, 2026, with the stock at $4.22, down from about $2.4 billion in mid-October. That valuation is about 10 times trailing revenue, a gap explained by expectations tied to the Papzimeos launch.
What are the biggest risks for PGEN?
+
The main risks are single-product concentration in Papzimeos, a valuation that still runs ahead of trailing revenue, the prospective launch of Inovio's competing RRP therapy, a thin cash balance (about $51 million at September 30, 2026, against about $98.6 million of debt) that could require dilutive financing if the ramp stalls, and a small target market. The stock has also been historically volatile, falling about 42% in the three months to November 20, 2026.
Who competes with Precigen?
+
In its lead RRP indication, the clearest pipeline rival is Inovio Pharmaceuticals with INO-3107. More broadly, PGEN sits among small gene- and cell-therapy biotechs, and its earlier programs touch immuno-oncology and HPV-disease areas where larger players like Merck operate.
Does Precigen pay a dividend?
+
No. Precigen does not pay a dividend. Like most launch-stage biotechs, it reinvests its resources into commercializing Papzimeos and advancing its pipeline rather than returning cash to shareholders.
How did Precigen do in its latest quarter?
+
In Q3 2026, reported November 4, Precigen posted revenue of about $74.1 million, up from about $55 million in Q2, as Papzimeos net product revenue rose 37% sequentially to about $72.9 million. Net income was about $35.8 million, or $0.08 per diluted share, matching the Yahoo Finance consensus, while revenue was slightly below the $75.4 million Zacks consensus. Operating cash flow turned positive a quarter ahead of guidance. Q4 consensus revenue is about $88 million.
How has PGEN stock performed in 2026?
+
PGEN closed at $4.22 on November 20, 2026, down about 1% year to date and up about 8% over the past year, within a 52-week range of $3.04 to $8.98. The shares fell about 42% over three months and about 32% in the most recent month, even as the Q3 report showed continued growth. Three analysts covering the stock had a mean price target of about $13.67.
Why has PGEN stock fallen since October 2026?
+
The shares dropped from about $6.75 in mid-October to $4.22 on November 20, 2026, roughly 37%, even though Q3 revenue grew and cash flow turned positive. Q3 revenue landed slightly below some estimates after a summer run-up, and the earnings call addressed the prospective launch of Inovio's competing RRP therapy. No single cause is confirmed, and Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Precigen, Inc.'s investor relations page or your broker before making investment decisions.